The completion of enrollment for the 201 Trial in untreated Parkinson’s disease represents a major milestone for Inhibikase,” said Milton H. Werner, PhD, Inhibikase’s president and CEO. “We look forward to reporting trial results in the fourth quarter, and the discussion with the FDA on our plans for pivotal Phase 3 trials by the end of the year.”
risvodetinib for Parkinson’s now fully en... - Cure Parkinson's
risvodetinib for Parkinson’s now fully enrolled
Written by
Farooqji
To view profiles and participate in discussions please or .
1 Reply
•
Following
Not what you're looking for?
You may also like...
Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months
prnewswire.com/news-releases/annovis-bio-announces-completion-of-phase-iii-parkinsons-disease-treatm
KARMET Study Begins Enrollment
https://www.prnewswire.com/news-releases/karmet-study-begins-enrollment-300775443.html
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
2019 and contemplates starting the two year Phase III trial in October of 2019, but the video says...
UC study: Subcutaneous infusion pump safe, effective for Parkinson’s treatment
of 381 patients with Parkinson’s disease in 16 countries enrolled in the trial and were randomized...
Houston Research Organization Successfully Treats 24 Patients in FDA-Authorized Parkinson’s Study
In this Phase II, double blind, placebo-controlled study, 24 patients received six intravenous...
Related Posts
A (minor) update by Inhibikase Therapeutics on their Phase 2 trial of Risvodetinib (IkT-148009) for Parkinson's Disease.
mucuna pruriens for people without Parkinson’s?
ENROLL for PD Research Study!
Hope bioscience is enrolling in 2 clinical trials 
Phase 3 trial of buntanetap for early-stage Parkinson’s nears end
